{"id":"W2494947788","doi":"10.1200/jco.2016.34.15_suppl.9007","title":"Brigatinib (BRG) in patients (pts) with crizotinib (CRZ)-refractory ALK+ non-small cell lung cancer (NSCLC): First report of efficacy and safety from a pivotal randomized phase (ph) 2 trial (ALTA).","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Crizotinib; Clinical endpoint; ALK inhibitor; Internal medicine; Refractory (planetary science); Lung cancer; non-small cell lung cancer (NSCLC); Response Evaluation Criteria in Solid Tumors; Ceritinib; Gastroenterology; Randomized controlled trial; Phases of clinical research; Clinical trial; Surgery; Oncology; Malignant pleural effusion","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007172549,0.0006381332,0.001328007,0.0002803716,0.0002123293,0.0005249302,0.0004082021,0.000649771,0.002893601],"category_scores_gemma":[0.0009343205,0.000385329,0.0005830631,0.0004273833,0.0003689823,0.0004432692,0.0002730356,0.001217671,0.0005430795],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007287043,"about_ca_system_score_gemma":0.0007321481,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009521637,"about_ca_topic_score_gemma":0.003763844,"domain_scores_codex":[0.9997595,0.0001214011,0.00002036686,0.00003659282,0.00002422576,0.00003796258],"domain_scores_gemma":[0.9997039,0.00005582218,0.00009046769,0.0000130063,0.00001352614,0.0001232531],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.797503,0.00858115,0.01909198,0.00155599,0.001095558,0.0004422272,0.000170924,0.00148649,0.0177325,0.0001705464,0.005310349,0.1468593],"study_design_scores_gemma":[0.6848939,0.2565539,0.04764483,0.0001209475,0.00108883,0.0007025649,0.00009643217,0.001349111,0.002171211,0.0002638297,0.00508181,0.0000326164],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9900539,0.00613717,0.0002007023,0.0005525021,0.00007841162,0.0009044483,0.0006625761,0.00006116192,0.001349301],"genre_scores_gemma":[0.9949509,0.002368758,0.0003915913,0.0004872637,0.00007958915,0.0004289414,0.0006492963,0.000006967221,0.0006366919],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002893601,"threshold_uncertainty_score":0.009680033,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03449083937050493,"score_gpt":0.4326835096161204,"score_spread":0.3981926702456154,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}